MCID: BRN071
MIFTS: 50

Brain Injury

Categories: Eye diseases, Mental diseases, Neuronal diseases

Aliases & Classifications for Brain Injury

MalaCards integrated aliases for Brain Injury:

Name: Brain Injury 53 37

Classifications:



Summaries for Brain Injury

NINDS : 53 Traumatic brain injury (TBI), a form of acquired brain injury, occurs when a sudden trauma causes damage to the brain. TBI can result when the head suddenly and violently hits an object, or when an object pierces the skull and enters brain tissue.  Symptoms of a TBI can be mild, moderate, or severe, depending on the extent of the damage to the brain. A person with a mild TBI may remain conscious or may experience a loss of consciousness for a few seconds or minutes. Other symptoms of mild TBI include headache, confusion, lightheadedness, dizziness, blurred vision or tired eyes, ringing in the ears, bad taste in the mouth, fatigue or lethargy, a change in sleep patterns, behavioral or mood changes, and trouble with memory, concentration, attention, or thinking.  A person with a moderate or severe TBI may show these same symptoms, but may also have a headache that gets worse or does not go away, repeated vomiting or nausea, convulsions or seizures, an inability to awaken from sleep, dilation of one or both pupils of the eyes, slurred speech, weakness or numbness in the extremities, loss of coordination, and increased confusion, restlessness, or agitation.

MalaCards based summary : Brain Injury is related to head injury and neonatal hypoxic and ischemic brain injury. An important gene associated with Brain Injury is TMEM158 (Transmembrane Protein 158), and among its related pathways/superpathways are MAPK signaling pathway and Prion disease. The drugs Diclofenac and Propranolol have been mentioned in the context of this disorder. Affiliated tissues include brain, cortex and spinal cord, and related phenotypes are cardiovascular system and behavior/neurological

Related Diseases for Brain Injury

Diseases related to Brain Injury via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1117)
# Related Disease Score Top Affiliating Genes
1 head injury 32.9 S100B ENO2 APOE
2 neonatal hypoxic and ischemic brain injury 32.5 MBP ENO2 BDNF
3 persistent vegetative state 32.2 ENO2 APOE
4 periventricular leukomalacia 32.1 MBP IL6 EPO
5 post-cardiac arrest syndrome 31.8 S100B IL6 ENO2
6 cerebral hypoxia 31.8 IGF1 CASP3
7 amnestic disorder 31.8 S100B MAPT BDNF APOE
8 post-traumatic stress disorder 31.6 IL1B DRD2 COMT BDNF APOE
9 cerebral artery occlusion 31.5 IL1B BDNF AQP4 APOE
10 ischemia 31.2 GFAP EPO CASP3 BDNF ASIC1
11 aphasia 31.2 MAPT BDNF APOE
12 status epilepticus 31.2 GFAP ENO2 CASP3 BDNF
13 dementia 31.2 UCHL1 MAPT GFAP DRD2 COMT BDNF
14 cardiac arrest 31.1 S100B EPO ENO2 ALB
15 agnosia 31.1 IL6 IL1B COMT BDNF ALB
16 mood disorder 31.1 IL6 GFAP DRD2 COMT BDNF
17 brain edema 31.0 IL6 IL1B GFAP AQP4 ALB
18 spinal cord injury 31.0 IL6 GFAP CASP3 BDNF AQP4
19 generalized anxiety disorder 31.0 DRD2 COMT BDNF
20 personality disorder 31.0 DRD2 COMT BDNF
21 cerebral palsy 30.9 S100B IL6 IL1B IGF1 BDNF APOE
22 normal pressure hydrocephalus 30.9 MAPT IGF1 GFAP BDNF AQP4 APOE
23 obsessive-compulsive disorder 30.9 IL6 IL1B IGF1 DRD2 COMT BDNF
24 alexithymia 30.9 IL6 DRD2 COMT
25 mental depression 30.8 IL6 IL1B DRD2 COMT BDNF
26 psychotic disorder 30.8 S100B DRD2 COMT BDNF
27 mild cognitive impairment 30.8 MAPT COMT BDNF APOE
28 anxiety 30.8 IL6 IL1B DRD2 COMT BDNF APOE
29 attention deficit-hyperactivity disorder 30.8 S100B IL6 DRD2 COMT BDNF
30 carotid artery occlusion 30.8 MBP IL1B GFAP CASP3 BDNF
31 substance abuse 30.7 IL6 DRD2 COMT BDNF ALB
32 alcohol use disorder 30.7 DRD2 COMT BDNF ALB
33 arteriovenous malformation 30.7 IL6 IL1B APOE
34 transient cerebral ischemia 30.7 MAPT IL1B CASP3
35 back pain 30.6 IL6 IL1B COMT
36 movement disease 30.6 MAPT DRD2 BDNF APOE
37 neurotic disorder 30.5 IL6 COMT BDNF
38 dysthymic disorder 30.5 IL6 COMT BDNF
39 substance dependence 30.5 IL6 DRD2 COMT BDNF
40 major depressive disorder 30.4 S100B IL6 IL1B DRD2 COMT BDNF
41 obstructive hydrocephalus 30.4 GFAP ENO2 AQP4
42 panic disorder 30.3 DRD2 COMT BDNF ASIC1
43 encephalitis 30.3 IL6 IL1B GFAP AQP4
44 fetal alcohol syndrome 30.3 GFAP CASP3 BDNF
45 borderline personality disorder 30.3 DRD2 COMT BDNF
46 akinetic mutism 30.3 S100B MBP MAPT ENO2
47 traumatic brain injury 30.3 UCHL1 SPTAN1 S100B MBP IL6 IL1B
48 ganglioglioma 30.2 S100B GFAP ENO2
49 cocaine dependence 30.2 DRD2 COMT BDNF
50 sexual disorder 30.2 IGF1 BDNF ALB

Graphical network of the top 20 diseases related to Brain Injury:



Diseases related to Brain Injury

Symptoms & Phenotypes for Brain Injury

MGI Mouse Phenotypes related to Brain Injury:

46 (show all 17)
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.43 ALB APOE AQP4 ASIC1 CASP3 COMT
2 behavior/neurological MP:0005386 10.41 APOE AQP4 ASIC1 BDNF CASP3 COMT
3 homeostasis/metabolism MP:0005376 10.4 ALB APOE AQP4 BDNF CASP3 COMT
4 growth/size/body region MP:0005378 10.37 APOE AQP4 BDNF CASP3 DRD2 ENO2
5 cellular MP:0005384 10.36 ALB APOE BDNF CASP3 DRD2 ENO2
6 immune system MP:0005387 10.32 ALB APOE AQP4 CASP3 COMT DRD2
7 mortality/aging MP:0010768 10.31 ALB APOE AQP4 BDNF CASP3 DRD2
8 hematopoietic system MP:0005397 10.29 APOE AQP4 CASP3 COMT DRD2 EPO
9 nervous system MP:0003631 10.22 APOE AQP4 ASIC1 BDNF CASP3 COMT
10 integument MP:0010771 10.2 APOE BDNF CASP3 DRD2 EPO IGF1
11 digestive/alimentary MP:0005381 10.19 ALB APOE AQP4 BDNF CASP3 DRD2
12 muscle MP:0005369 10.06 ALB APOE CASP3 DRD2 EPO GFAP
13 normal MP:0002873 9.96 ALB BDNF DRD2 EPO GFAP IGF1
14 neoplasm MP:0002006 9.91 ALB DRD2 IGF1 IL1B IL6 MAPT
15 renal/urinary system MP:0005367 9.85 ALB APOE AQP4 CASP3 COMT DRD2
16 respiratory system MP:0005388 9.7 APOE AQP4 BDNF CASP3 COMT DRD2
17 taste/olfaction MP:0005394 9.1 APOE BDNF CASP3 DRD2 ENO2 MAPT

Drugs & Therapeutics for Brain Injury

Drugs for Brain Injury (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 387)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Diclofenac Approved, Vet_approved Phase 4 15307-86-5 3033
2
Propranolol Approved, Investigational Phase 4 525-66-6 4946
3
Testosterone undecanoate Approved, Investigational Phase 4 5949-44-0
4
Testosterone enanthate Approved Phase 4 315-37-7 9416
5
Testosterone Approved, Investigational Phase 4 58-22-0 6013
6
Methyltestosterone Approved Phase 4 58-18-4 6010
7
Dalteparin Approved Phase 4 9005-49-6
8
Tinzaparin Approved Phase 4 9041-08-1, 9005-49-6 25244225
9
Citalopram Approved Phase 4 59729-33-8 2771
10
Doxycycline Approved, Investigational, Vet_approved Phase 4 564-25-0 54671203
11
Simvastatin Approved Phase 4 79902-63-9 54454
12
Exenatide Approved, Investigational Phase 4 141758-74-9 15991534
13
Cisatracurium Approved Phase 4 96946-41-7 62887
14
Donepezil Approved Phase 4 120014-06-4 3152
15
Amitriptyline Approved Phase 4 50-48-6 2160
16 Prednisolone acetate Approved, Vet_approved Phase 4 52-21-1
17
Pramipexole Approved, Investigational Phase 4 104632-26-0 59868 119570
18
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
19
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
20
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
21
Aspirin Approved, Vet_approved Phase 4 50-78-2 2244
22
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5
23
Rotigotine Approved Phase 4 99755-59-6, 92206-54-7 57537
24
Clopidogrel Approved Phase 4 120202-66-6, 113665-84-2 60606
25
Valproic acid Approved, Investigational Phase 4 99-66-1 3121
26
Sumatriptan Approved, Investigational Phase 4 103628-46-2 5358
27
Zolmitriptan Approved, Investigational Phase 4 139264-17-8 441240 60857
28
Rivastigmine Approved, Investigational Phase 4 123441-03-2 77991
29
Pregabalin Approved, Investigational Phase 4 148553-50-8 5486971
30
Lamotrigine Approved, Investigational Phase 4 84057-84-1 3878
31
Rizatriptan Approved Phase 4 144034-80-0, 145202-66-0 5078
32
Amantadine Approved Phase 4 768-94-5 2130
33
Buspirone Approved, Investigational Phase 4 36505-84-7 2477
34
Huperzine A Approved, Experimental Phase 4 102518-79-6
35
Mannitol Approved, Investigational Phase 4 69-65-8 453 6251
36
Hydrocortisone acetate Approved, Vet_approved Phase 4 50-03-3
37
Hydrocortisone Approved, Vet_approved Phase 4 50-23-7 5754
38
Benzocaine Approved, Investigational Phase 4 1994-09-7, 94-09-7 2337
39
tannic acid Approved Phase 4 1401-55-4
40
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
41
Memantine Approved, Investigational Phase 4 19982-08-2 4054
42
Racepinephrine Approved Phase 4 329-65-7 838
43
Epinephrine Approved, Vet_approved Phase 4 51-43-4 5816
44
Zinc Approved, Investigational Phase 4 7440-66-6 32051
45
Choline Approved, Nutraceutical Phase 4 62-49-7 305
46
Vitamin A Approved, Nutraceutical, Vet_approved Phase 4 68-26-8, 11103-57-4 445354
47
Melatonin Approved, Nutraceutical, Vet_approved Phase 4 73-31-4 896
48
Prednisolone hemisuccinate Experimental Phase 4 2920-86-7
49 Cytidine Diphosphate Choline Phase 4
50 retinol Phase 4

Interventional clinical trials:

(show top 50) (show all 1406)
# Name Status NCT ID Phase Drugs
1 A Randomised Control Trial to Determine the Effectiveness of Sensory Stimulation Program in Reducing the Length of Time Spent by Severely Brain Injured Patients in a Vegetative State in the Acute Hospital Environment Unknown status NCT00163878 Phase 4
2 A Clinical Trial of the Effect of Midazolam on the Cerebral Metabolism and Inflammatory Response in Patients With Moderate and Severe Traumatic Brain Injury Unknown status NCT02071407 Phase 4 Midazolam;Placebo
3 Efficiency and Tolerance of a Small-peptide Enteral Feeding Formula Compared to a Whole-protein Formula in the Critically Ill Patient : a Prospective Randomized Trial Unknown status NCT01833624 Phase 4
4 Normothermia in Patients With Acute Cerebral Damage Unknown status NCT00491192 Phase 4 Diclofenac
5 Effect of Amantadine Administration on Spatial Functioning Following Traumatic Brain Injury Unknown status NCT02321761 Phase 4 Amantadine hydrochloride
6 Randomized Controlled Clinical Study of Intensive Versus Nonintensive Insulin Therapy for Hyperglycemia After Traumatic Brain Injury Unknown status NCT02161055 Phase 4 Insulin
7 A Randomized Controlled Trial of Antidepressant Maintenance for Major Depression Following Mild Traumatic Brain Injury Unknown status NCT00162916 Phase 4 citalopram;Placebo
8 Pilot Study: The Effect of Rozerem on Sleep Disturbance After Traumatic Brain Injury Unknown status NCT01207050 Phase 4 Ramelteon
9 Citicholine-Amantadine Trial in Traumatic Brain Injury Unknown status NCT03430817 Phase 4 Citicholine;Amantadine
10 Effect of Erythropoietin on Preterm Brain Injury Completed NCT02036073 Phase 4 recombinant human erythropoietin
11 Equimolar Doses of Mannitol and Hypertonic Saline in the Treatment of Elevated Intracranial Pressure Completed NCT00447018 Phase 4 20% mannitol;7.45% hypertonic saline solution
12 Pharmacological Intervention in Depression After Traumatic Brain Injury (A Research Study Within the Traumatic Brain Injury Model System) Completed NCT00205491 Phase 4 Venlafaxine
13 Using Propranolol in Traumatic Brain Injury to Reduce Sympathetic Storm Phenomenon: A Prospective Randomized Clinical Trial Injury to Reduce Sympathetic Storm Phenomenon: A Prospective Randomized Clinical Trial Completed NCT03401515 Phase 4 Propranolol Hydrochloride 1 MG/ML
14 Improvement of Therapy in Patients With Severe Traumatic Brain Injury: Differential Impact of Local and Systemic Changes and Routinely Applied Drugs Completed NCT02130674 Phase 4 Dipeptiven
15 Assessment of Seizure Prophylaxis Protocols Using Intravenous Levetiracetam in a Neuroscience Intensive Care Unit Completed NCT00618436 Phase 4 Levetiracetam;Phenytoin
16 Bispectral Index Value Changes During Induction and Surgical Decompression in Head Injury Patients Completed NCT03480880 Phase 4
17 Efficacy of Methylphenidate for Management of Long-Term Attention Problems After Pediatric Traumatic Brain Injury (TBI) Completed NCT01933217 Phase 4 Methylphenidate;Placebo
18 Amantadine Hydrochloride for Treatment of Symptoms of the Post-traumatic Confusional State Among Neurorehabilitation Admissions With TBI: A Randomized, Double-Blind, Placebo-Controlled Trial Completed NCT00693121 Phase 4 Amantadine hydrochloride;Placebo capsule
19 Phase IV Study of Cognitive Rehabilitation Effectiveness for Mild Traumatic Brain Injury Completed NCT01339806 Phase 4
20 Doxycycline Effects on Neurological Outcomes in Patients With Acute Traumatic Brain Injury Completed NCT04239755 Phase 4 Doxycycline 100 MG Oral Tablet
21 Treatment Outcomes With Lisdexamfetamine Dimesylate (Vyvanse) in Children With Traumatic Brain Injury-Related Attention Deficits Completed NCT02712996 Phase 4 Lisdexamfetamine;Placebo
22 Simvastatin: Proof-of-Concept for Prevention of Neurodegeneration in Mild TBI Completed NCT01952288 Phase 4 simvastatin;Placebo Oral Tablet
23 Topiramate Treatment of Hazardous and Harmful Alcohol Use in Veterans With TBI Completed NCT01750268 Phase 4 Topiramate;Placebo
24 The Control of Brain Networks After Traumatic Brain Injury: a Neuroimaging and Neuropsychological Study of Dopamine and Cognition Completed NCT02015949 Phase 4 Methylphenidate;Placebo
25 A 26-Week Open-Label Extension to Protocol No. CENA713BUS11: A 12-Week, Prospective, Double-blind, Placebo-controlled, Multi-center Study Evaluating the Efficacy and Safety of Rivastigmine 3 to 6 mg/Day in Patients With Traumatic Brain Injury (TBI) With Persistent Cognitive Deficits Completed NCT00219245 Phase 4 Rivastigmine
26 The Use of Low Molecular Weight Heparin in Traumatic Brain Injury Completed NCT00170378 Phase 4 Enoxaparin
27 Intravenous Exenatide Infusion in Critically Ill Patients With Acute Brain Injury Completed NCT02058940 Phase 4 Exenatide
28 Pediatric Traumatic Brain Injury: Methylphenidate Effects on Early Recovery Completed NCT00035139 Phase 4 methylphenidate
29 Beta-Adrenergic Blockade for Suppression of Catecholamine Surge Following Traumatic Brain Injury: A Randomized Trial Completed NCT02957331 Phase 4 Propranolol
30 The Serotonin Transporter Gene Polymorphism and Major Depression Following Traumatic Brain Injury Completed NCT00254007 Phase 4 citalopram (celexa)
31 Neuroendocrine Dysfunction in Traumatic Brain Injury: Effects of Testosterone Therapy Completed NCT01201863 Phase 4 Androgel (Testosterone Gel);Androgel Placebo
32 Anterior Pituitary Hormone Replacement in Traumatic Brain Injury Completed NCT00957671 Phase 4 Recombinant human growth hormone
33 Cerebral Protection of Dexmedetomidine Against Paroxysmal Sympathetic Overexcited in Patients With Traumatic Brain Injury Recruiting NCT04006054 Phase 4 Dexmedetomidine;Midazolam
34 Does Short-Term Anti-Seizure Prophylaxis After Traumatic Brain Injury Decrease Seizure Rates? Recruiting NCT03054285 Phase 4 Levetiracetam
35 Potential Impact of Amantadine on Traumatic Brain Injury Outcomes Recruiting NCT04527289 Phase 4 Amantadine (100mg) as add on therapy.;Placebo
36 Treatment of Intracranial Hypertension of Severe Tramatic Brain Injured Patients. Physiopathologic Effects of Neuromuscular Blocking Agents. A Controlled Randomized Study Versus Placebo Recruiting NCT02404779 Phase 4 cisatracurium besilate
37 MLC901 for Moderate to Severe Traumatic Brain Injury: Pilot, Randomized, Double-Masked, Placebo-controlled Trial Recruiting NCT04487275 Phase 4 MLC901 or Placebo
38 NEUROTHERM: The Effect of Paracetamol on Brain Temperature in Acute Brain Injury in a Neuro Critical Care Unit: A Randomized Controlled Trial Recruiting NCT03648021 Phase 4 Paracetamol;Placebo
39 Quality Improvement and Practice Based Research in Neurology Using the Electronic Medical Record Enrolling by invitation NCT02670161 Phase 4 Listed for each disorder below, up to three drugs per disorder (too many characters to list in this field; see Intervention Description)
40 Beta Blocker Use In Traumatic Brain Injury Based On The High-Sensitive Troponin T Status: A Randomized Controlled Trial (BBTBBT) Not yet recruiting NCT04508244 Phase 4 Placebo;Propranolol
41 Combination Treatment With Cerebrolysin and Amantadine on Prolonged Disorders of Consciousness in Patients With Severe Traumatic Brain Injury: A Pilot Study Not yet recruiting NCT04427241 Phase 4 Amantadine Sulfate plus Cerebrolysin;Amantadine Sulfate;Cerebrolysin
42 A Randomized, Controlled, Single-center Clinical Study of Huperzine A in the Treatment of Brain Injury in Patients With Hypertensive Cerebral Hemorrhage Not yet recruiting NCT04509323 Phase 4 Huperzine A for Injection
43 Non-Invasive Vagal Nerve Stimulation in Veterans With Mild Traumatic Brain Injury (mTBI) Not yet recruiting NCT04437498 Phase 4
44 Buspirone and Melatonin for Depression Following Traumatic Brain Injury Not yet recruiting NCT04400266 Phase 4 B+MEL
45 Propofol Versus Midazolam for Sedation in Mechanically Ventilated Critically Ill Patients Who Presented With Traumatic Brain Injury: Cytokine Response and Neuropsychological Assessment (IRRC#1201M) Terminated NCT01712477 Phase 4 Intravenous sedation using propofol;Intravenous sedation with midazolam
46 Double-blind Cross-over Study of the Effect of Namenda on Short Term Memory and Attention in Patients With Mild to Moderate Traumatic Brain Injury, Protocol NAM-MD-44 Terminated NCT00462228 Phase 4 Memantine;Placebo
47 Combining Observational and Physiologic Sedation Assessment Tools Terminated NCT00538369 Phase 4
48 A Randomized, Double-blind, Placebo-controlled Trial to Investigate Safety and Efficacy of Cerebrolysin in Patients With Traumatic Brain Injury Terminated NCT01606111 Phase 4 Cerebrolysin;0.9% NaCl, saline
49 Compared Effects of 2 Doses of Mannitol on Post Traumatic Intracranial Hypertension Terminated NCT00795587 Phase 4 variation of mannitol dose
50 Functional Vision Consequences of Rehabilitation for TBI Vision Loss Terminated NCT01214070 Phase 4

Search NIH Clinical Center for Brain Injury

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Brain Injury cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Brain Injury:
Hematopoietic stem cells for treatment of ischemic brain injury
Embryonic/Adult Cultured Cells Related to Brain Injury:
Bone marrow-derived hematopoietic stem cells (family)

Genetic Tests for Brain Injury

Anatomical Context for Brain Injury

MalaCards organs/tissues related to Brain Injury:

40
Brain, Cortex, Spinal Cord, Pituitary, Endothelial, Bone Marrow, Eye

Publications for Brain Injury

Articles related to Brain Injury:

(show top 50) (show all 30000)
# Title Authors PMID Year
1
A nomogram based on serum cystatin C for predicting acute kidney injury in patients with traumatic brain injury. 61
33478333 2021
2
Eucalyptol ameliorates early brain injury after subarachnoid haemorrhage via antioxidant and anti-inflammatory effects in a rat model. 61
33550883 2021
3
Inhibition of nitric oxide synthase aggravates brain injury in diabetic rats with traumatic brain injury. 61
33433486 2021
4
Hydroxyethylstarch revisited for acute brain injury treatment. 61
33318420 2021
5
Comparative transcriptomic analysis of rat versus mouse cerebral cortex after traumatic brain injury. 61
33318400 2021
6
Brief inhalation of sevoflurane can reduce glial scar formation after hypoxic-ischemic brain injury in neonatal rats. 61
33269750 2021
7
Collagen/heparan sulfate porous scaffolds loaded with neural stem cells improve neurological function in a rat model of traumatic brain injury. 61
33269752 2021
8
Emergence of the Wallerian degeneration pathway as a mechanism of secondary brain injury. 61
33229742 2021
9
Longitudinal study of quality of life in acquired brain injury: A self- and proxy-report evaluation. 61
33552163 2021
10
Targeting chronic and evolving neuroinflammation following traumatic brain injury to improve long-term outcomes: insights from microglial-depletion models. 61
33229740 2021
11
Impact of pediatric traumatic brain injury on hippocampal neurogenesis. 61
33229731 2021
12
Evaluation of diffusion measurements reveals radial diffusivity indicative of microstructural damage following acute, mild traumatic brain injury. 61
33359428 2021
13
Tibetan medicine Duoxuekang ameliorates hypobaric hypoxia-induced brain injury in mice by restoration of cerebrovascular function. 61
33246120 2021
14
ER stress mediated‑autophagy contributes to neurological dysfunction in traumatic brain injury via the ATF6 UPR signaling pathway. 61
33537827 2021
15
Experimental diffuse brain injury and a model of Alzheimer's disease exhibit disease-specific changes in sleep and incongruous peripheral inflammation. 61
33319441 2021
16
A "hot Spot"-Enhanced paper lateral flow assay for ultrasensitive detection of traumatic brain injury biomarker S-100β in blood plasma. 61
33429202 2021
17
MicroRNA-376b-5p targets SOX7 to alleviate ischemic brain injury in a mouse model through activating Wnt/β-catenin signaling pathway. 61
33482187 2021
18
Heat shock protein 22 modulates NRF1/TFAM-dependent mitochondrial biogenesis and DRP1-sparked mitochondrial apoptosis through AMPK-PGC1α signaling pathway to alleviate the early brain injury of subarachnoid hemorrhage in rats. 61
33472123 2021
19
Prognostic value of CT perfusion and permeability imaging in traumatic brain injury. 61
33009337 2021
20
Subcallosal haemorrhage as a sign of diffuse axonal injury in patients with traumatic brain injury. 61
33160606 2021
21
Cognition in patients with traumatic brain injury measured by the Montreal Cognitive Assessment-Basic. 61
31060382 2021
22
Injury during adolescence leads to sex-specific executive function deficits in adulthood in a pre-clinical model of mild traumatic brain injury. 61
33333110 2021
23
Astaxanthin ameliorates oxidative stress and neuronal apoptosis via SIRT1/NRF2/Prx2/ASK1/p38 after traumatic brain injury in mice. 61
33326114 2021
24
Paeoniflorin treatment regulates TLR4/NF-κB signaling, reduces cerebral oxidative stress and improves white matter integrity in neonatal hypoxic brain injury. 61
33602880 2021
25
Optical coherence tomography microscopy in experimental traumatic brain injury. 61
33009699 2021
26
Outcome after surgical stabilization of rib fractures versus nonoperative treatment in patients with multiple rib fractures and moderate to severe traumatic brain injury (CWIS-TBI). 61
33093293 2021
27
The Role of Acid Sphingomyelinase Inhibition in Repetitive Mild Traumatic Brain Injury. 61
33131764 2021
28
Biomolecular alterations in acute traumatic brain injury (TBI) using Fourier transform infrared (FTIR) imaging spectroscopy. 61
33277210 2021
29
Recombinant Human Growth Hormone Activates Neuroprotective Growth Factors in Hypoxic Brain Injury in Neonatal Mice. 61
33545716 2021
30
Geographical Variation in Traumatic Brain Injury Mortality by Proximity to the Nearest Neurosurgeon. 61
33070997 2021
31
The Effect of Childhood Traumatic Brain Injury on Verbal Fluency Performance: A Systematic Review and Meta-Analysis. 61
33398784 2021
32
This time it's personal: reappraisal after acquired brain injury. 61
33153409 2021
33
Exploring participation after paediatric acquired brain injury. 61
32067469 2021
34
Deletion of ferritin H in neurons counteracts the protective effect of melatonin against traumatic brain injury-induced ferroptosis. 61
33206394 2021
35
Neuroprotective Effect of Fractalkine on Radiation-induced Brain Injury Through Promoting the M2 Polarization of Microglia. 61
33089423 2021
36
What is known about the cost-effectiveness of neuropsychological interventions for individuals with acquired brain injury? A scoping review. 61
31769336 2021
37
Performance on the repeatable battery for the assessment of neuropsychological status in college students with mild traumatic brain injury. 61
31230481 2021
38
Gut microbiota-brain interaction: An emerging immunotherapy for traumatic brain injury. 61
33370556 2021
39
Worse Than Death: Survey of Public Perceptions of Disability Outcomes After Hypothetical Traumatic Brain Injury. 61
31972638 2021
40
Temporal changes in inflammatory mitochondria-enriched microRNAs following traumatic brain injury and effects of miR-146a nanoparticle delivery. 61
32985480 2021
41
Effects of Acute Subdural Hematoma-Induced Brain Injury On Energy Metabolism in Peripheral Blood Mononuclear Cells. 61
32826816 2021
42
Proton extrusion during oxidative burst in microglia exacerbates pathological acidosis following traumatic brain injury. 61
33090575 2021
43
Care of the Patient with Acquired Brain Injury in Latin America and the Caribbean. 61
33526195 2021
44
Caring for Traumatic Brain Injury Patients: Australian Nursing Perspectives. 61
33526196 2021
45
Reply to comment on 'An elderly patient with Alzheimer's disease, normal pressure hydrocephalus and traumatic brain injury: presented with behavioral symptoms similar to behavioral variant frontotemporal dementia? 61
32122209 2021
46
Biopsychosocial Factors Associated With Attention Problems in Children After Traumatic Brain Injury: A Systematic Review. 61
33229886 2021
47
Traumatic Brain Injury: Does Admission Service Matter? 61
33310498 2021
48
Neuro-regenerative imidazole-functionalized GelMA hydrogel loaded with hAMSC and SDF-1α promote stem cell differentiation and repair focal brain injury. 61
33005827 2021
49
Epigenetic Blockade of Hippocampal SOD2 Via DNMT3b-Mediated DNA Methylation: Implications in Mild Traumatic Brain Injury-Induced Persistent Oxidative Damage. 61
33099744 2021
50
Papaverine provides neuroprotection by suppressing neuroinflammation and apoptosis in the traumatic brain injury via RAGE- NF-<kappa>B pathway. 61
33476858 2021

Variations for Brain Injury

Expression for Brain Injury

Search GEO for disease gene expression data for Brain Injury.

Pathways for Brain Injury

GO Terms for Brain Injury

Cellular components related to Brain Injury according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.97 S100B IL6 IL1B IGF1 EPO ENO2
2 dendrite GO:0030425 9.8 MAPT DRD2 COMT BDNF APOE
3 axon GO:0030424 9.77 UCHL1 MAPT DRD2 COMT BDNF
4 extracellular region GO:0005576 9.7 SPTAN1 S100B MAPT IL6 IL1B IGF1
5 cell body GO:0044297 9.46 MAPT GFAP EPO COMT
6 astrocyte end-foot GO:0097450 9.26 GFAP AQP4
7 neuronal cell body GO:0043025 9.1 UCHL1 MBP MAPT ENO2 CASP3 APOE

Biological processes related to Brain Injury according to GeneCards Suite gene sharing:

(show all 12)
# Name GO ID Score Top Affiliating Genes
1 cellular protein metabolic process GO:0044267 9.76 IL6 IGF1 APOE ALB
2 memory GO:0007613 9.69 MAPT BDNF ASIC1
3 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.61 IL6 IGF1 EPO
4 learning or memory GO:0007611 9.58 S100B MAPT CASP3
5 response to lipopolysaccharide GO:0032496 9.56 IL1B EPO COMT CASP3
6 synapse assembly GO:0007416 9.54 MAPT DRD2 BDNF
7 negative regulation of synaptic transmission GO:0050805 9.49 IL1B DRD2
8 axonal transport of mitochondrion GO:0019896 9.48 UCHL1 MAPT
9 negative regulation of MAP kinase activity GO:0043407 9.33 UCHL1 IL1B APOE
10 vascular endothelial growth factor production GO:0010573 9.32 IL6 IL1B
11 regulation of neurotransmitter uptake GO:0051580 8.96 GFAP DRD2
12 positive regulation of glial cell proliferation GO:0060252 8.8 IL6 IL1B GFAP

Molecular functions related to Brain Injury according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 lipoprotein particle binding GO:0071813 8.62 MAPT APOE

Sources for Brain Injury

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Mar-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....